Hector F. DeLuca, is a founder of Deltanoid Pharmaceuticals,
Inc. and is recognized as one of the world leaders in vitamin
D chemistry, biochemistry and medicine, holding more than
200 patents in the United States and more than 1,200 patents
in other countries. Prior to establishing Deltanoid, Dr.
DeLuca was involved in the development of eight drugs marketed
worldwide with over $10 Billion in worldwide sales, including
Alfarol®, Zemplar® Rocaltrol®, Hectorol® and
several others. Dr. DeLuca has been a successful entrepreneur
involved in the creation of the publicly held pharmaceutical
firm Bone Care International (NASDAQ:BCII).
Because of his expertise in the field of vitamin D, Dr.
DeLuca has developed contacts with many major pharmaceutical
companies world-wide, and serves as a consultant to many
firms. Dr. DeLuca continues his affiliation with the University
of Wisconsin-Madison as Professor and retired from 30 years as Chairman of the Biochemistry
Department in 2005. He received his PhD in biochemistry from the
University of Wisconsin-Madison.
Margaret Clagett-Dame is a founder of Deltanoid Pharmaceuticals,
Inc. and is known for her considerable experience in both
vitamin A and vitamin D, and has over 70 patents to her
credit. Dr. Clagett-Dame also brings experience in the
pharmaceutical industry with one of the top 10 pharmaceutical
companies in the U.S. Since 1989, Dr. Clagett-Dame
has been a professor at the University of Wisconsin-Madison
in both the Department of Biochemistry and School of Pharmacy.
She obtained her MS in Nutrition from the Pennsylvania
State University and a PhD in Biochemistry from the University
Dr. Lori Plum brings over 15 years of experience in vitamin
A and vitamin D research, and has worked in the University
laboratories of both Drs. Clagett-Dame and DeLuca. She has over 50 patents to her credit.
Dr. Plum attended North Dakota State University-Fargo where she received her BS in
Nutrition and received her PhD in Nutritional Sciences from the University of Wisconsin-Madison.
Linda Leikness brings over 20 years of management experience
in entrepreneurial environments and biotechnology to Deltanoid.
Prior to joining Deltanoid, Ms. Leikness worked as Chief
Financial Officer and Treasurer for PanVera Corporation, now owned by
Invitrogen (NASDAQ:IVGN), and also worked as Chief Financial
Officer for Pleasant Company/American Girl, which was sold
to Mattel (NYSE:MAT). Ms. Leikness received her degree in Accounting
from the University of Wisconsin- Milwaukee and is a Certified Public
Accountant and Certified Management Accountant.